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Abstract DC Bead is a drug delivery embolisation
system that can be loaded with doxorubicin or irinotecan
for the treatment of a variety of liver cancers. In this study
we demonstrate that the topoisomerase I inhibitor topo-
tecan hydrochloride can be successfully loaded into the
DC Bead sulfonate-modified polyvinyl alcohol hydrogel
matrix, resulting in a sustained-release drug eluting bead
(DEBTOP) useful for therapeutic purposes. The in vitro
drug loading capacity, elution characteristics and the
effects on mechanical properties of the beads are described
with reference to our previous work with irinotecan
hydrochloride (DEBIRI). Results showed that drug loading
was faster when the solution was agitated compared to
static loading and a maximum loading of ca. 40–45 mg
topotecan in 1 ml hydrated beads was achievable. Loading
the drug into the beads altered the size, compressibility
moduli and colour of the bead. Elution was shown to be
reliant on the presence of ions to perform the necessary
exchange with the electrostatically bound topotecan mol-
ecules. Topotecan was shown by MTS assay to have an
IC50 for human pancreatic adenocarcinoma cells (PSN-1)
of 0.22 and 0.27 lM compared to 28.1 and 19.2 lM for
irinotecan at 48 and 72 h, respectively. The cytotoxic
efficacy of DEBTOP on PSN-1 was compared to DEBIRI.
DEPTOP loaded at 6 & 30 mg ml-1, like its free drug
form, was shown to be more potent than DEBIRI of
comparable doses at 24, 48 & 72 h using a slightly modi-
fied MTS assay. Using a PSN-1 mouse xenograft model,
DEBIRI doses of 3.3–6.6 mg were shown to be well-
tolerated (even with repeat administration) and effective in
reducing the tumour size. DEBTOP however, was lethal
after 6 days at doses of 0.83–1.2 mg but demonstrated
reasonable efficacy and tolerability (again with repeat
injection possible) at 0.2–0.4 mg doses. Care must there-
fore be taken when selecting the dose of topotecan to be
loaded into DC Bead given its greater potency and poten-
tial toxicity.
1 Introduction
Topotecan is a semi-synthetic analogue of camptothecin,
a chemotherapeutic agent derived from Camptothecan
acuminata, the oriental yew. The cytotoxic mode of action
of this family of compounds is understood to be related to
their ability to bind and inhibit the enzyme type 1 topoi-
somerase (Topo-1), which is involved in the replication and
repair of DNA during the S-phase of the cell cycle [1]. As
DNA is replicated in dividing cells, Topo-1 acts by binding
to super-coiled DNA and causing controlled single-stran-
ded breaks which relieve the torsional stresses that are
introduced into DNA ahead of the replication complex or
moving replication fork. Topotecan inhibits Topo-1 by
stabilizing the covalent complex of enzyme and strand-
cleaved DNA, inducing uncontrolled single and double
strand breaks in the DNA and damage to the replication
fork which results in cell death. Topotecan is expected to
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possess a degree of selectivity in its cytotoxic action, as
cell division is more frequent and there are higher levels of
Topo-1 in malignant cells compared to normal cells [2]. Its
chemical structure consists of a fused ring structure con-
taining a lactone ring which is vital to its Topo-1 binding
action. The lactone is hydrolysed at neutral pH and above
to form the open-ring carboxylate which is inactive; hence,
it is important to the activity of any formulation of this
drug that the closed ring lactone form is maintained.
DC Bead has been recently commercialised and used
successfully in the clinic for the local treatment of hepato-
cellular carcinoma [3–5], various neuroendocrine metasta-
ses [6] and colorectal cancer metastases to the liver [7, 8]
by transarterial chemoembolisation (TACE) of the feeding
arteries of the malignancies. More recent preclinical studies
have shown that it is feasible to administer DC Bead by
other routes, for instance by intraperitoneal (IP) injection
for the treatment of peritoneal carcinomatosis [9], or by
direct intratumoral (IT) injection as a therapy for glioblas-
toma multiforme [10]. The DC Bead is based upon a sul-
fonate-modified polyvinyl alcohol hydrogel, which permits
loading and subsequent delivery of variety of positively-
charged chemotherapeutic agents including doxorubicin,
mitoxantrone and irinotecan [11–13]. The beads are avail-
able in a number of size ranges from 100–300 lm,
300–500 lm and 500–700 lm, with the two smaller size
ranges being most popular for embolisation of tumours. It
has been demonstrated that affinity between drug and bead
is promoted by the ionic interaction of their opposite
charges. In the case of irinotecan (another water-soluble
camptothecin derivative), the lactone ring formation is
maintained intact by this ionic interaction which drives the
equilibrium in favour of the positively-charged lactone
form over the zwitterionic carboxylate [14].
Topotecan is available as a formulated product known
commercially as Hycamptin containing as the active ingre-
dient topotecan hydrochloride. It is positively charged by
virtue of the pendent dimethylamine hydrochloride salt,
which differs somewhat to that of the salt formed on the
dipiperidino ring of irinotecan. It does, however, possess
the same lactone-ring structure as irinotecan and could be
expected to benefit from the same mode of preservation of
the active form [14] (Fig. 1). Irinotecan is a prodrug that
requires the cleavage of the dipiperidino side chain by
carboxylesterases present in the body to generate the more
potent active metabolite SN-38. Topotecan does not require
this enzymatic activation and is therefore used in very much
lower doses (typically 1–2 mg m-2 compared to several
hundred mg m-2 for irinotecan [15]). The early uses of
topotecan as a chemotherapeutic agent have been in the
treatment of ovarian cancer and small cell lung cancer
(SCLC) but studies have also been performed in the treat-
ment of brain tumours [16]. Its systemic use has significant
side effects including diarrhoea, neutropenia and increased
susceptibility to infection. It therefore possesses several
attributes that make it an excellent candidate to consider for
local delivery using DEB: high potency but with systemic
toxicity; active against a range of cancer types; positively
charged salt for ionic interaction; available in a formulation
that could be used to load the drug immediately prior to a
procedure (as is currently performed using DC Bead to load
doxorubicin or irinotecan prior to a TACE procedure [17]).
The loading efficacy of irinotecan has already been estab-
lished [17]. In this study we present in vitro characterisation
of DEBTOP, with respect to drug loading capacity, elution
characteristics, mechanical properties of the device and
some preliminary investigations into efficacy using an in
vitro and in vivo pancreatic carcinoma models.
2 Materials and methods
2.1 Materials
Topotecan hydrochloride powder (Dabur Pharma Ltd.,
Ghaziabad, India) was dissolved in distilled water ([17.0
MX) to produce appropriate loading solutions. DC Bead
(sulfonate-modified polyvinyl alcohol hydrogel beads from
Biocompatibles UK Ltd., Farnham, UK) were used in the
size range of 300–500 lm to assess drug loading, elution
and cell viability, due to ease of handling compared to the
smaller size. 100–300 lm beads were used for animal
studies as the tumours themselves were only 0.2 cm3 and
the smallest available size product was most appropriate
for small gauge needle delivery. In order to ensure the
beads were retained at the site of injection and not
extravasated, they were suspended in a 0.6 wt/vol alginate
solution (ultra-pure Phycomer E01, CellMed AG, Alzenau,
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Fig. 1 Chemical structure of DC Bead and its proposed interaction
with the active lactone (L) form of topotecan. The active lactone form
is believed to bind to the DEBs and elute in this form. Once eluted
topotecan can behave like free topotecan and converts to the more
stable inactive carboxylate (C) form
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Germany) which is mannuronic acid rich and has a
molecular weight of approximately 800,000 and hence
helps to increase viscosity of the suspension. For
compressibility studies, DC Bead in the size range of
900–1200 lm were used as these produce the most con-
sistent mechanical data. Solutions used in loading and
elution analysis included a 50:50 mix (v/v) of ethanol
(Romil Ltd., UK): saturated potassium chloride solution
(Fisher Scientific UK Ltd., UK) and phosphate buffered
saline solution (PBS) (Inverclyde Biologicals, UK) solu-
tions respectively.
2.2 Preparation of DEBTOP and determination of drug
loading level
DEBTOP was prepared by removing the packing solution
from 1 ml of 300–500 lm DC Bead and then adding the
drug solution to the vial containing the bead slurry. In order
to assess the maximum loading capacity, DC Bead was
exposed to topotecan solutions containing between 2 and
100 mg for 3 h. The vials were agitated on a roller mixer.
To determine total dose loaded, the loaded beads were
removed from their solution, transferred to 500 ml of 50:50
mix of ethanol: saturated KCl solution and stirred at
700 rpm for 7 h. Use of this rapid-elution medium ensured
that all drug was extracted from the beads [12]. This was
confirmed by use of HPLC analysis of the extraction
solution and mass balance comparison with any residual
drug remaining in the loading solution. The HPLC setup
comprised of a C18 reverse phased column and an 85:15
water:acetonitrile with 0.1% trifluoroacetic acid mobile
phase pumped at 1.2 ml min-1 (isocratic). The mobile
phase was \pH 3 to ensure that topotecan present was
converted to its lactone form to aid analysis. The injection
volume was 20 ll and the sample was detected using UV
absorption at 228 nm.
To assess the effect of agitated loading, beads exposed
to 6 mg topotecan (6 ml, 1 mg ml-1 solution) were either
roller-mixed during loading or left static for three hours. A
100 ll aliquot of the loading solution was removed from
the sample at set time points over three hours and diluted
with 900 ll of water prior to HPLC analysis as described
above.
2.3 Bead sizing and appearance
The size and appearance of individual DC Beads during
topotecan loading and elution were examined by use of an
Olympus BX50F4 microscope with a Colorview III Cam-
era (Olympus, Japan), under an aqueous solution. Sizing
data were analysed using AnalySIS (Soft Imaging System
GmbH) software.
2.4 Compressibility of DEBTOP
Analysis of DC Bead compressibility was conducted with
900–1200 lm beads as the technique was less sensitive for
smaller beads. DC Bead with and without drug loading
under an aqueous solution was assessed using an Instron
4411 with Series IX software (Instron, Canton, MA, USA)
as previously described [17]. The general procedure
involved distributing the beads onto a specially-fabricated
sample holder on the Instron to form a monolayer of about
7–10 mm in width. The residual water around the beads
was carefully removed by wicking using a filter paper. The
diameter of the probe used was 5.0 mm with a crosshead
speed of 5.0 mm min-1. The load cell used was 50 N and
the specimen gauge length was set as 1.0 mm. All the
experiments were carried out at room temperature.
The load and compression modulus was calculated from
the slope of the curve versus percentage strain at 8–16%
compression strain. Five measurements were performed
per sample at room temperature.
2.5 In vitro release of topotecan into various media
The elution profiles of DEBTOP were evaluated in PBS at
room temperature. Two loading doses were assessed; 6 mg
(low) and 30 mg (high) topotecan ml-1 hydrated DC
Bead. The loaded beads were then extracted into 500 ml of
PBS at room temperature by stirring with a magnetic
stirrer at a speed of 700 rpm. A 1.5 ml aliquot of the
elution solution was removed from the sample at set times
over 7 h and analysed by HPLC. The percentage of
topotecan eluted from the beads was then calculated as a
function of time.
2.6 In vitro PSN-1 cytotoxicity
Human pancreatic adenocarcinoma (PSN-1) cells (pur-
chased frozen from ECACC UK, 94060601) were seeded
at a density of 20,000 cells per well (96 well plate) in
RPMI (PAA, UK) media containing 10% Fetal Bovine
Serum, (PAA, UK). The cells were incubated under stan-
dard conditions (5% CO2, 37C) overnight. The media was
then removed and replaced with either free topotecan or
irinotecan concentrations (0.00001–1000 lg ml-1 media)
or a single topotecan or irinotecan loaded DC Bead (6 and
30 mg drug ml-1 DC Bead) in 200 ll of media. An MTS
assay (Promega, UK) was used to determine to number of
viable cells at 24, 48 and 72 h. Cell viability was expressed
as a percentage of control (untreated) cells. Differences in
cell viabilities were analysed using a Bonferroni Student’s
t-test with a P value of\0.05 being defined as statistically
significant.
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2.7 In vivo nude mouse xenograft
Animal studies were performed by Exp. Pharmacol. &
Oncol. GmbH, (Berlin-Buch, Germany) in accordance with
local regulations (granted by the LAGeSo, State Office of
Health and Social Affairs, Berlin). PSN-1 tumour pieces
(human pancreatic carcinoma) were prepared from an in
vitro passage for subcutaneous transplantation in female
nude mice. Mice were randomised to the scheduled treat-
ment groups (n = 3 per group). When the tumours became
palpable (0.2 cm3), the DC Bead/alginate mixture was
injected close to the subcutaneous growing tumour, using a
1 ml syringe (B.Braun, Germany) fitted with a G16 needle
(0.6 9 25 mm, Terumo Europe, Belgium). Prior to injec-
tion all the lyophilised gamma-sterilised DC Bead (1 ml
pre dehydration) were hydrated on the day of administra-
tion by the addition of 3 ml alginate solution. The delivery
volume was 100 ll or 200 ll per mouse. In some cases,
when the mean tumour size was C20% larger than the
previous time point a repeat injection was performed at a
different site next to the tumour compared to the previous
injection. The doses and volumes injected are shown in
Table 3. Tumour volumes and body weights were recorded
twice weekly. Mice were sacrificed when the tumours
reached an average size of [1 cm3.
3 Results and discussion
3.1 Topotecan loading profiles
The available topotecan is adsorbed in a linear fashion
(R2 = 0.999) relative to the loading solution concentration
into DC Bead at a dose matching &88% of the available
drug, up to 35 mg (Fig. 2). The residual salt within the
packing solution exchanging with ionically bound topotecan
was thought to be the reason that all of the available topo-
tecan only loaded to&88%. The loading appears to plateau
at a maximum around 40–45 mg topotecan ml-1 of unloa-
ded DC Bead. These data suggest that all the binding sites
are saturated, so even if more topotecan is available it cannot
bind to the bead, merely partition into its water fraction. The
binding interaction between the drug and bead is attributed
to the negatively charged sulfonate group within the bead
and the positively charged protonated amine group on the
topotecan molecule (Fig. 1). The calculated theoretical
number of available binding sites (sulfonate groups) in 1 ml
beads is 7.7 9 10-5 mol [17]. This would equate to a
loading of 35 mg, which is less than the observed maximum
loading. This indicates that more than one topotecan mole-
cule is binding per sulfonate group. This could be achieved
by the drug interacting with itself as it becomes concentrated
in the bead matrix. It is known in the literature that topotecan
does form dimers at high concentrations [18].
It was observed that topotecan partitioned into DC Bead
from the 6 mg loading solution faster when the system was
agitated compared to stationary loading (Fig. 3). The larger
error associated with static loading was attributed to
unintentional solution movement when sample was
removed for analysis. Agitation helps to disturb the elec-
trical double-layer build up of ions at the beads surface
which otherwise impedes the loading process in the static
situation. Loading was achieved in \20 min when DC
Bead was agitated; it is considered that this would be an
acceptable time for DC Bead preparation in the pharmacy
prior to use.
3.2 Bead sizing and appearance
Post topotecan loading, DC Bead exhibited a yellow/green
hue, which was more intense upon higher drug loading.
This colour was due to a combination of the blue tint of the
microsphere and the inherent yellow/green colour of the
0
5
10
15
20
25
30
35
40
45
0 10 20 30 40 50 60 70 80 90 100
Available Topotecan in Loading Solution (mg)T
op
ot
ec
an
 E
xt
ra
ct
ed
 fr
om
 1
 m
L 
DE
B 
(m
g)
A B C
Fig. 2 Topotecan bound to 1 ml of DC Bead compared to the
available topotecan. Inset: Light microscopy images (94 magnifica-
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Fig. 3 Loading profile of 6 mg topotecan into DC Bead when (d)
agitated or (h) static (n = 6, mean ± SD)
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drug (Fig. 2, inset). The bead size was shown to decrease
with higher topotecan loading (Table 1).
3.3 Compressibility
The compression properties of the beads provide an indi-
cation of how they will deform when passing through a
microcatheter, needle or blood vessel. Compared to the
unloaded beads, DC Bead, topotecan loaded exhibited
significantly higher compression moduli. Resistance to
compression was associated with increased drug loading
(Table 2). The increase in compression and decrease in
bead size with drug loading were attributed to the hydro-
phobic nature of the topotecan molecules displacing the
water molecules from the hydrogel. Similar phenomena
were observed with doxorubicin and irinotecan loaded DC
Bead [17]. In addition, the change in compression and bead
size may be exaggerated due to the association capabilities
of topotecan, which is able to self-aggregate at higher
concentrations to form dimers [18]. This may act as extra
crosslinking junctions, consequently decreasing the dis-
tance between polymer chains (reducing bead size),
expelling water and increasing resistance to compression.
3.4 In vitro drug release
Topotecan elution is retarded by its interaction with the DC
Bead. Figure 4 shows that the elution is dependent on the
amount of topotecan loaded. At lower loading (6 mg)
topotecan has fully eluted from the DC Bead after 30 min,
whilst at higher loading (30 mg) the drug takes around
180 min to fully elute. Topotecan did not elute from DC
Bead when the elution medium was water, but was liber-
ated from the beads when the medium was changed to
phosphate buffered saline (PBS) (Fig. 4, inset). PBS, a
medium more representative of biological fluids, facilitates
the release of topotecan through ion exchange; a process
not available in distilled water.
The diffusion coefficient, D, for this system was calcu-
lated using the method described by Taylor [17]. The D
values when \85% of the loaded drug was eluted were
2.6 9 10-7 and 5.9 9 10-8 cm2 s-1 for the 6 and
30 mg ml-1 loadings respectively. The diffusion coeffi-
cient decreases with increasing drug loading and the dif-
ference in topotecan elution can be attributed to the higher
hydrophobicity of topotecan or potential dimerisation of
topotecan, both resulting in drug-drug interaction and
possessing a tighter network through which the drug must
permeate.
3.5 In vitro PSN-1 cytotoxicity
Pancreatic adenocarcinoma cells were used as a model to
test the efficacy of topotecan and irinotecan delivery from
DC Bead. Topotecan has been prescribed in patients with
advanced pancreatic cancer in clinical models but was not
very successful in the dosing regimes attempted. A dose
administered as a 30 min infusion at a dose of 1.5 mg m-2
day-1 for five consecutive days every 3 weeks has been
shown to exhibit toxicity (neutropenia) and no significant
antitumour responses [19]. Alternative dosing regimes at
0.5 mg m-2 day-1 over 21 days exhibited 8% partial
response, with reversible and non-cumulative toxicity
(myelosuppression) [20]. Localised therapies may offer a
method for enhancing efficacy and reducing systemic side
effects in vivo and we have shown in the previous sections
Table 1 Topotecan loaded ml-1 DC Bead and corresponding
diameter (n = 200)
Topotecan loaded (mg) Size (lm)
Mean Std. Dev.
0 445 63
2 457 73
4 427 61
6 435 69
10 431 57
30 340 47
Table 2 Topotecan loaded ml-1 DC Bead and corresponding com-
pression modulus (n = 200)
Topotecan loaded (mg) Modulus (kPa)
Average Std. Dev.
0 36 2
6 40 2
30 95 10
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Fig. 4 Elution profiles of (D) 6 mg and (j) 30 mg topotecan
extracted from 300 to 500 lm beads into PBS (% elution) at room
temperature (n = 6, mean ± SD). Inset: (‘‘Elution’’ of topotecan into
water then PBS (D) 6 mg ml-1 DEBs (j) 30 mg ml-1 (n = 1))
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that DEBTOP can be easily loaded and the drug eluted in a
controlled manner.
Using the MTS assay, both topotecan and irinotecan in
their free drug form showed cytotoxicity towards pancre-
atic adenocarcinoma (PSN-1) cells. The IC50 for irinotecan
at 72 h was 19.2 lM, slightly higher than the 1–10 lM
range reported previously [21]. The cytotoxicity of topo-
tecan was greater than irinotecan at the same concentra-
tions for all time points as demonstrated by an IC50 some
two orders of magnitude less (Table 3, Fig. 5). The IC50
values obtained for topotecan were not dissimilar to those
obtained by other workers using MCF-7 human breast
cancer [22] or U87 human glioma cell lines [23], which for
comparison were in the range 0.037–0.280 lM. At earlier
time points and lower concentrations both drugs elicited a
small increase in cell number, which is thought to be a
cellular response to stress. At higher concentrations and
later time points, cellular death was observed. Interestingly,
at the highest concentration for both drugs at 72 h, the
cytotoxicity was slightly less than the corresponding 48 h
data, indicating possible drug-resistance mechanisms may
be initiated. When exposed to a single topotecan loaded
DC Bead, reduction in PSN-1 cell viability was observed
for both 6 and 30 mg ml-1 loadings at statistically greater
levels than for the corresponding DEBIRI (Fig. 6). For
comparison, DEBIRI exhibited signs of cytotoxicity after
48 and 72 h, but not at 24 h. Topotecan is cytotoxic when
eluted from the DC Bead, indicating that topotecan main-
tains its activity upon elution. The comparison with
DEBIRI highlights the greater potency of topotecan despite
their matching concentrations.
3.6 In vivo mouse PSN-1 xenograft response
The growth of PSN-1 tumours was inhibited with DEBTOP
or DEBIRI administered subcutaneously in nude mice
(Table 4, Fig. 7). The higher doses of topotecan (1.2 and
0.83 mg) were lethal to all the mice after six days, whilst
the lower concentrations (0.4 and 0.2 mg) showed some
efficacy in reducing the tumour volume. The control mice
showed severe body weight loss when the tumours reached
a larger tumour volume, which was attributed to tumour
induced cachexia. Based on this measure of toxicity, all
groups (except the toxic higher topotecan doses) showed no
significant weight loss, indicating that the treatments were
well tolerated.
In agreement with the in vitro results, a much lower dose
of topotecan was required to elicit a cytotoxic effect
compared to irinotecan. From all of the samples tested
here, the higher irinotecan dose showed the greatest
potential for survival for 57 days post the tumour implant.
Table 3 Irinotecan hydrochloride and topotecan hydrochloride IC50
for PSN-1 cells
Drug IC50 mg ml
-1 IC50 lM
48 h 72 h 48 h 72 h
Irinotecan 13 19 28.1 19.2
Topotecan 0.101 0.123 0.27 0.22
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Table 4 Group information for mouse xenograft study
Group Bead
type
Amount of drug
loaded per ml of
beads
Total volume
(alginate and DEB)
injected (ll)
Dose
(mg)
A Unloaded 0 100 0
B DEBIRI 100 100 3.3
C 100 200 6.6
D DEBTOP 37 100 1.2
E 25 100 0.83
F 12 100 0.4
G 6 100 0.2
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Two mice from this group demonstrated significant tumour
shrinkage, with one demonstrating [99% shrinkage after
47 days and no signs of regrowth after 57 days. One mouse
in this group did demonstrate significant tumour growth
after 36 days. The variability in the groups may be due to
inconsistencies in the exact location of the injection site
relative to the tumour; moreover, the tumours grow het-
erogeneously and sometimes have a capsule, areas with
necrotic tissue or larger blood vessels, the variation from
which will have been further exacerbated by the low
number of animals per group. In the higher irinotecan dose
treatment, an increase in tumour size was observed after
19 days. Whilst this could either be due to drug resistance
or insufficient drug, the reduction in tumour size after the
second injection demonstrates that the initial growth is
likely due to the latter effect (Fig. 7).
4 Conclusions
In summary, topotecan can be easily loaded into DC Bead
within 20 min when the solution and beads are agitated.
The process is slower without agitation as the loading is
reliant upon diffusion. As has been seen with doxorubicin
and irinotecan, loading with higher concentrations of
topotecan changed the colour as well as size and com-
pressibility of the DC Bead. These factors changed within
the expected range and were markedly different at higher
(30 mg ml-1) concentrations. The release from 1 ml DC
Bead took 30 or 180 min to fully elute in a PBS sink
environment for 6 and 30 mg topotecan loading respec-
tively. Topotecan efficacy against human pancreatic car-
cinoma cells was demonstrated in vitro both as a free drug
and from DEBTOP, where it was shown to be more potent
with an IC50 two orders of magnitude lower than DEBIRI.
Both irinotecan and topotecan demonstrate the capacity to
be loaded and eluted from DC Bead and show efficacy in a
nude mouse human pancreatic adenoma xenograft model.
The best treatment (DEBIRI) reduced the tumour by[99%
in one mouse, extending the average time it took for the
tumour to become 1 cm3 in size from 13 to 57 days and
demonstrated the feasibility and tolerability of repeat direct
injections. Higher doses of topotecan (0.83–1.2 mg) how-
ever, were lethal at 6 days post injection, which serves to
highlight that dose selection is still critical when consid-
ering the balance between efficacy and severe toxicity/
death. Overall, the treatment with either DEBIRI or
DEBTOP was well tolerated and could be considered as a
method to treat pancreatic cancer either through direct
injection or via arterial administration.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and source are credited.
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